ASMQ
Cipla
3-day cure, artemisinin-based combination therapies (TPP-1)
Artesunate- mefloquine
Access
-
Approved
Therapeutic indication |
|
Dosing |
|
Efficacy |
|
Key features |
|
Challenges |
|
Status |
|
Previously |
|
Project Director |
|
* ACPR = adequate clinical and parasitological response